Amarin Corp Plcuk (AMRN) Accumulated Expenses (2010 - 2026)
Amarin Corp Plcuk (AMRN) reported Accumulated Expenses of $131.5 million for Q1 2026, up 12.63% year-over-year from $116.7 million in Q1 2025, and down 11.81% quarter-over-quarter from $149.1 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Accumulated Expenses (2010 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 17 years of Accumulated Expenses data on file, last reported at $131.5 million in Q1 2026.
- Accumulated Expenses for Q1 2026 came in at $131.5 million, up 12.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $131.5 million (up 12.63% YoY), and the FY2025 annual result was $149.1 million, up 870.6% from the prior year.
- Accumulated Expenses fell to $131.5 million in Q1 2026 per AMRN's latest filing, from $149.1 million in the prior quarter.
- Over five years, Accumulated Expenses peaked at $243.1 million in Q2 2022 and troughed at $3.6 million in Q4 2023.
- A 5-year average of $145.1 million and a median of $154.4 million in 2024 frame the typical range for Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2025: Accumulated Expenses sank 82.33% in 2023, then surged 870.6% in 2025.
- A 5-year view of Accumulated Expenses shows it stood at $20.3 million in 2022, then tumbled by 82.33% to $3.6 million in 2023, then jumped by 328.27% to $15.4 million in 2024, then surged by 870.6% to $149.1 million in 2025, then slipped by 11.81% to $131.5 million in 2026.
- Business Quant data shows AMRN's Accumulated Expenses at $131.5 million in Q1 2026, $149.1 million in Q4 2025, and $145.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 131.49 Mn |
| Dec 31, 2025 | 149.10 Mn |
| Sep 30, 2025 | 145.52 Mn |
| Jun 30, 2025 | 141.24 Mn |
| Mar 31, 2025 | 116.75 Mn |
| Dec 31, 2024 | 15.36 Mn |
| Sep 30, 2024 | 161.05 Mn |
| Jun 30, 2024 | 176.16 Mn |
| Mar 31, 2024 | 154.44 Mn |
| Dec 31, 2023 | 3.59 Mn |
| Sep 30, 2023 | 211.30 Mn |
| Jun 30, 2023 | 214.60 Mn |
| Mar 31, 2023 | 183.26 Mn |
| Dec 31, 2022 | 20.30 Mn |
| Sep 30, 2022 | 192.00 Mn |
| Jun 30, 2022 | 243.06 Mn |
| Mar 31, 2022 | 207.62 Mn |
| Dec 31, 2021 | 3.56 Mn |
| Sep 30, 2021 | 289.68 Mn |
| Jun 30, 2021 | 226.55 Mn |